Ochiai T, Sato H, Isono K, Uematsu T, Nakajima K, Mukai M, Asano T, Onoda S, Morioka Y, Danno M
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):959-69.
A multi-center study was performed to clarify the immunological effects of MY-1, a new biological response modifier, on postoperative gastric cancer patients. A total of 90 patients were randomly allocated either to an MY-1 treated or an untreated group. MY-1 was given 3 times a week from the 4th postoperative day for a period of 3 weeks. Immunological parameters of the patients, such as lymphocyte subsets measured with flow cytometry using various monoclonal antibodies, blast transformation responses against PHA, ConA, and PPD, natural killer activity of peripheral lymphocytes, and skin test for MY-1 and PPD, were evaluated preoperatively, before and after MY-1 treatment. The results of the two color staining method with flow cytometry showed that the population of lymphocytes positive for both OKT8 and Leu15 antigens (suppressor cells) was statistically less, and that the population of lymphocytes positive for OKT8 and negative for Leu15 antigens (killer cells) was statistically increased in patients treated with MY-1 compared with the control group.
进行了一项多中心研究，以阐明新型生物反应调节剂MY-1对胃癌术后患者的免疫作用。总共90例患者被随机分为MY-1治疗组或未治疗组。从术后第4天开始，每周3次给予MY-1，持续3周。在术前、MY-1治疗前后，评估患者的免疫参数，如使用各种单克隆抗体通过流式细胞术测量淋巴细胞亚群、对PHA、ConA和PPD的淋巴细胞转化反应、外周淋巴细胞的自然杀伤活性以及对MY-1和PPD的皮肤试验。流式细胞术双色染色法的结果显示，与对照组相比，接受MY-1治疗的患者中，OKT8和Leu15抗原均呈阳性的淋巴细胞群体（抑制细胞）在统计学上较少，而OKT8呈阳性且Leu15抗原呈阴性的淋巴细胞群体（杀伤细胞）在统计学上有所增加。
